Navigation Links
Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
Date:5/7/2008

ently and with partners, including Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the protocol, design, scope, enrollment and other aspects of current and planned clinical trials and other studies of Arena's or its collaborators' product candidates and compounds; the future results of clinical trials; the tolerability, side effects, efficacy and potential of Arena's or its collaborators' product candidates and compounds; an NDA submission for lorcaserin and the potential partnering and commercialization of the drug candidate; expectations relating to the agreements and Arena's relationship with Siegfried; the advancement and content of Arena's pipeline; and other statements about Arena's outlook, strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of clinical trials or preclinical studies may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, the timing and receip
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... SAN DIEGO, Aug. 29, 2014  Pfenex Inc. ... in the development of high-value and difficult to ... business update and reported financial results for the ... "With the successful completion of our initial public ... advance our biosimilar product candidates, derived from our ...
(Date:8/29/2014)... are based on electrons, but one of the most ... i.e. circuits based on light (photons) instead of electrons. ... a stream of single photons and control their direction. ... attempts to achieve this control, but now scientists at ... steady stream of photons emitted one at a time ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 The ... $5.6 billion in 2019. It is expected to ... to 2019, and was valued at $1.8 billion ... by Transparency Market Research. , For more information ... http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research report, titled “Companion ...
(Date:8/29/2014)... 29, 2014 According to a new market ... global orthobiologics market was valued at USD 3,754.6 million in ... 5,519.9million in 2019at a CAGR of 5.9% from 2013 to ... and above is afflicted by bone and joint disorders, and ... 2020. This has and will continue to increase the demand ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Breakthrough in light sources for new quantum technology 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3
... Solutions, LLC, Santa Clara, CA, a manufacturer of ... Nova Biomedical, Waltham, MA, a world leader in ... TruBio(TM) plug-in for OPC connectivity between TruBio control ... de facto standard for data exchange between process ...
... CITY, March 6 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... company focused on endocrine therapy and oncology, will announce ... results before market open on Wednesday, March 11, 2009. ... to discuss these results later that same day at ...
... Plants to Further Develop Plant Traits for BiofuelKINGSTON, ... (PPI), a global leader in agricultural and biofuel ... are pleased to announce that a project led ... in funding from SDTC. The funds will be ...
Cached Biology Technology:UPDATE: OPC Connectivity Between TruBio Software and Nova FLEX Analyzers 2Canadian Government Announces Funding for Leading Biotechnology Firm's Project 2Canadian Government Announces Funding for Leading Biotechnology Firm's Project 3
(Date:8/29/2014)... Davis have made some surprising discoveries about the ... immunodeficiency virus (SIV), the team found that specialized ... early responders to viral invasion and are the ... called interleukin-1 beta (IL-1β). , Though aimed ... of the gut epithelium that provides a barrier ...
(Date:8/29/2014)... Scientists at the Barshop Institute for Longevity and ... the UT Health Science Center at San Antonio, have ... the longest-lived rodent, the naked mole rat. , ... naked mole rats protects and alters the activity of ... proteins. , The factor also protects proteasome function in ...
(Date:8/29/2014)... little has been known about what genetic changes transform ... scientists, one of whom is a University of Montana ... genes controlling the development of the brain and the ... study was published Aug. 28 in Science ... online at http://www.sciencemag.org/ ., The domestication of animals ...
Breaking Biology News(10 mins):The early cost of HIV 2Factor in naked mole rat's cells enhances protein integrity 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3
... DALLAS May 11, 2010 Microbiologists at UT Southwestern ... a potential target in cattle that could be exploited to ... strain of Escherichia coli . In the ... Proceedings of the National Academy of Sciences , researchers ...
... The car is not the only vehicle that can ... Engineering Technical School, Mikel Lejarza, Jose Ignacio Uriarte, Miguel ngel ... research team working on an innovative project: to have a ... and unmooring) using electric energy obtained from the movement of ...
... 2010) -- Cell-cell junctions are multi-molecular complexes that ... as barriers to permeability, and allow intercellular transport. ... Spring Harbor Laboratory Press, surveys current research on cell ... University) and W. James Nelson (Stanford University), both leaders ...
Cached Biology News:UT Southwestern researchers find mechanism that may stop E. coli from developing in cattle 2Project for sailing vessels to maneuver in ports using electric energy from wind 2Project for sailing vessels to maneuver in ports using electric energy from wind 3
KV beta.1 (Q-13)...
Preadipocyte factor-1 [Pref-1, DLK-1], C-terminal...
... 4 deuterium atoms at the 3, 3', ... for use as an internal standard for ... GC- or LC-mass spectrometry. PGE2 is one ... acid and one of the most widely ...
Deletions, insertions or substitutions. Mutations in plasmids of size up to 15 kb. Single or multiple mutations...
Biology Products: